firazyr
(icatibant acetate)Takeda Pharmaceuticals America, Inc.
Usage: FIRAZYR® (icatibant) is indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adults aged 18 years and older.
5 results
icatibant
(Icatibant)Alembic Pharmaceuticals Inc.Usage: Icatibant injection is indicated for treating acute attacks of hereditary angioedema (HAE) in adults aged 18 years and older.kalbitor
(Ecallantide)Takeda Pharmaceuticals America, Inc.Usage: KALBITOR (ecallantide) is indicated for the treatment of acute attacks of hereditary angioedema (HAE) in patients aged 12 and older.sajazir
(ICATIBANT)Cycle Pharmaceuticals Ltd-UkUsage: SAJAZIR (icatibant) injection is indicated for treating acute attacks of hereditary angioedema (HAE) in adults aged 18 and older.takhzyro
(lanadelumab-flyo)Takeda Pharmaceuticals America, Inc.Usage: TAKHZYRO® is indicated for the prophylaxis of hereditary angioedema (HAE) attacks in adults and pediatric patients aged 2 years and older.